Related Experiment Video
Updated: Dec 8, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19)
Pablo Zubiaur1,2, Dora Koller1, Miriam Saiz-Rodríguez1,3
1Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Abstract:
In December 2019, the severe acute respiratory syndrome virus-2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off-label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Single Nucleotide Polymorphisms-SNPs
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacokinetics: Drug–Drug Interactions
Pharmacodynamics in Geriatric Patients: Effects of Age
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

